Related Experiment Video
Updated: Aug 25, 2026
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Potential impact of conjugate pneumococcal vaccines on pediatric pneumococcal diseases
Katherine L O'Brien1, Mathuram Santosham
1Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. klobrien@jhsph.edu
Insights
Pneumococcal conjugate vaccines (PnCRM-7) offer significant protection against invasive pneumococcal disease and otitis media in children under two. Routine immunization is expected to reduce disease burden and healthcare costs.
Area of Science:
- Pediatrics
- Vaccinology
- Infectious Diseases
Background:
- Children under age 2 have the highest rates of invasive pneumococcal disease (IPD) and are key in its transmission.
- Seven pneumococcal serotypes cause 80% of IPD and 60% of middle-ear infections in young children, often with penicillin resistance.
- Existing polysaccharide vaccines are ineffective in children under 2 and do not prevent otitis media or carriage.
Purpose of the Study:
- To evaluate the efficacy and immunogenicity of a new pneumococcal conjugate vaccine for young children.
- To assess the impact of the seven-valent conjugate vaccine (PnCRM-7) on invasive pneumococcal disease and otitis media.
Main Methods:
- Development of a novel pneumococcal vaccine linking capsular polysaccharides to a protein carrier.
- Approval and administration of the seven-valent conjugate vaccine (PnCRM-7) to children under age 2.
- Clinical evaluation of vaccine effectiveness against specific serotypes.
Main Results:
- PnCRM-7 demonstrates higher immunogenicity compared to older polysaccharide vaccines.
- The vaccine is 80-100% effective against vaccine-type invasive pneumococcal disease.
- PnCRM-7 shows 50-60% effectiveness against vaccine-type pneumococcal otitis media.
Conclusions:
- Routine immunization with PnCRM-7 is recommended for children under age 2.
- The vaccine is expected to significantly decrease the morbidity, mortality, and economic burden of pneumococcal disease.
- This conjugate vaccine represents a major advancement in pediatric infectious disease prevention.
Abstract:
Children younger than age 2 years have the highest rates of invasive pneumococcal disease and play an important role in its transmission. In the United States, seven pneumococcal serotypes cause approximately 80% of invasive disease and represent approximately 60% of middle-ear isolates in children younger than age 2 years; the majority of penicillin-resistant strains are confined to these same few serogroups. Although unconjugated polysaccharide pneumococcal vaccines have demonstrated effectiveness in preventing invasive disease in adults, these vaccines fail to protect against otitis media or nasopharyngeal carriage and are poorly immunogenic in children younger than age 2 years. A new generation of pneumococcal vaccines has been developed, linking the capsular polysaccharide of seven to 11 serotypes to a protein carrier. The only pneumococcal vaccine approved to date for children younger than age 2 years is a seven-valent conjugate vaccine (PnCRM-7) (Prevnar; Wyeth Vaccines, Pearl River, New York), which contains serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. PnCRM-7 is more immunogenic than the polysaccharide pneumococcal vaccines and is 80-100% effective against vaccine-type invasive disease and 50-60% effective against vaccine-type pneumococcal otitis media. Routine immunization with pneumococcal conjugate vaccines should substantially reduce the morbidity, mortality, and costs associated with pneumococcal disease in children.
Related Concept Videos
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:29Pneumonia I: Introduction
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:51Vaccinations
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption